At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 6,540 enrolled
Drug / intervention
MMRvaxpro +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Measles-mumps-rubella Vaccine at 6 Months of Age, Immunology, and Childhood Morbidity in a High-income Setting
In Brief
A Phase 4 clinical trial evaluating MMRvaxpro and Placebo for Meales-mumps-rubella Vaccine. Completed, enrolled 6,540 participants across 2 sites.
Detailed Summary
Randomised, double-blind clinical trial to test humoral and cellular immunogenicity, and potential in-direct beneficial effect of the MMRvaxpro-vaccine administered at 6 months of age
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeales-mumps-rubella Vaccine
CountriesDenmark
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartApr 2019
Primary CompletionJan 2022
TodayJul 2026
First PostedDec 19, 2018
Enrollment StartApr 15, 2019
Primary CompletionJan 7, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.5 years ago
Interventions
MMRvaxprobiological
MMRvaxpro vaccine
Placebobiological
Placebo